ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $159,188 | +4.9% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $151,725 | +41.5% | 1,700 | +70.0% | 0.00% | +100.0% |
| Q1 2023 | $107,220 | +75.6% | 1,000 | +100.0% | 0.00% | 0.0% |
| Q4 2022 | $61,065 | -98.6% | 500 | -98.8% | 0.00% | -97.8% |
| Q3 2022 | $4,254,000 | +12.5% | 41,200 | +1.2% | 0.05% | +21.1% |
| Q2 2022 | $3,783,000 | -20.8% | 40,700 | 0.0% | 0.04% | -19.1% |
| Q1 2022 | $4,776,000 | – | 40,700 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |